Tratamento farmacológico da cardiomiopatia hipertrófica em adultos - uma revisão narrativa / Pharmacological treatment of hypertrophic cardiomyopathy in adults - a narrative review

Artur Ferri Leite Storino, Thaís Moreira Martins da Costa, Norma Ávila da Silveira, Tainá Ávila da Silveira, João Ricardo Arraes Oliveira, Bruna Pereira Vilaça, Jéssica Cunha, Nathan Shuenck Silva de Oliveira, Vítor Barcelos Fagundes

Abstract


INTRODUÇÃO: A cardiomiopatia hipertrófica (CMH) é a mais prevalente cardiopatia de etiologia genética, mas são escassos estudos de adequado rigor metodológico que avaliem a segurança e eficácia do tratamento farmacológico dessa patologia. O objetivo deste artigo é revisar a literatura com abordagem do tratamento farmacológico da CMH em pacientes adultos. METODOLOGIA: Realizou-se revisão bibliográfica narrativa. As bases de dados PubMed, Embase e Scopus foram pesquisadas, aplicando-se a estratégia de busca: (Hypertrophic cardiomyopathy) AND (Drug therapy) NOT (Case Reports[Publication Type]), com os filtros: últimos 5 anos, língua portuguesa e inglesa e adultos com mais de 19 anos. Foram selecionados estudos que avaliassem o tratamento farmacológico da CMH em pacientes adultos. RESULTADOS E DISCUSSÃO: Os principais aspectos contemplados pela terapia medicamentosa da CMH em adultos incluem: manejo da obstrução de via de saída do VE; alívio da sintomatologia em pacientes com cardiomiopatia hipertrófica não-obstrutiva; e controle de arritmias. Ademais, destacam-se novos esquemas terapêuticos que visam a remissão da hipertrofia/fibrose miocárdicas. CONCLUSÃO: Já existem variadas opções farmacológicas que se mostraram eficazes no controle sintomatológico em pacientes adultos portadores de CMH, e novas alternativas têm sido avaliadas pela comunidade científica, visando ampliar o arsenal terapêutico para o combate a essa patologia.


Keywords


Adulto, Cardiomiopatia hipertrófica, Tratamento farmacológico.

References


ADLER, A. et al. Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients. Journal of The American Heart Association, v. 6, n. 6, 2017.

AMMIRATI, E. et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. European Journal of Heart Failure, v. 18, n. 9, p. 1106-1118, 2016.

ANTUNES, M.O.; SCUDELER, T.L. Hypertrophic cardiomyopathy. IJC Heart & Vasculature, v. 27, p. 100503, 2020.

AXELSSON, A. et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology, v. 3, n. 2, p. 123-131, 2015.

AXELSSON, A. et al. Functional effects of losartan in hypertrophic cardiomyopathy—a randomised clinical trial. Heart, v. 102, n. 4, p. 285-291, 2016.

BITTENCOURT, M.I.; ROCHA, R.M; FILHO, F.M.A. Cardiomiopatia Hipertrófica. Revista Brasileira de Cardiologia, v. 23, n.1, p. 17-24, 2010.

COATS, C.J.; et al. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA Cardiology, v. 4, n. 3, p. 230–235, 2019.

DOMINGUEZ, F. et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. International Journal of Cardiology, v. 248, p. 232-238, 2017.

ELLIOTT, P.M. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, v. 35, n. 39, p. 2733-2779, 2014.

FERRANTINI, C.; et al. Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. British Journal of Pharmacology, v. 175, n. 13. p. 2635-2652, jul. 2018.

GARG, L. et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart failure reviews, v. 24, n. 2, p. 189-197, 2019.

GENTRY, J. L. et al. Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). Journal of the American College of Cardiology, v.68, n.16, p. 1815-1817, 2016.

GUTTMANN, O.P. et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart, v. 103, n. 9, p. 672–678, 2017.

HABIB, M. et al. Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy. International Journal Of Cardiology, v. 297, p. 75-82, 2019.

HAMADA, M. et al. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy. Journal Of Cardiology, v. 67, n. 3, p. 279-286, 2016.

HUANG, Chen-Yu et al. Renin–angiotensin–aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy. Heart, v. 104, n. 15, p. 1276-1283, 2018.

JUNG, H. et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. Chest, v. 155, n. 2, p. 354-363, 2019.

MARIAN, A.J. et al. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM) A Randomized, Placebo-Controlled, Double-Blind Pilot Study. Circulation Research, v. 122, n. 8, p. 1109-1118, 2018.

MARON, B.J.; MARON, M.S. Hypertrophic cardiomyopathy. Lancet, v. 381, n. 9862, p. 242-255, 2013.

MARON, M.S. et al. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. The American Journal of Medicine, v.131, n.7. p.837-841, 2018.

MILLER, C.A.S. et al. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. The American Journal Of Cardiology, v. 123, n. 11. p. 1859-1862, 2019.

MOORE, J.C. et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. Pacing and Clinical Electrophysiology, v. 41, n. 4, p. 396-401, 2018.

NOSEWORTHY, P.A. et al. Stroke and bleeding risks in NOAC-and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation. Journal of the American College of Cardiology, v. 67, n. 25, p. 3020-3021, 2016.

SHIMADA, Y.J. et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC: Heart Failure, v. 1, n. 6, p. 480-487, 2013.




DOI: https://doi.org/10.34119/bjhrv3n4-345

Refbacks

  • There are currently no refbacks.